文献速递关节外科创伤骨科

初次全髋关节置换术后假体周围感染翻修患者的死亡率增加

Increased Mortality After Prosthetic Joint Infection in Primary THA.
PubMed 文献 · Clin Orthop Relat Res · 2017-02-24

这项基于丹麦髋关节置换登记库的全国性队列研究纳入2005至2014年68504例初次全髋关节置换,其中445例因假体周围感染(PJI)翻修、1350例因其他原因翻修、66709例未翻修。初次置换后1年内因PJI翻修者死亡率为8%(95%CI 6%-11%),调整后相对死亡风险为未翻修者的2.18倍(95%CI 1.54-3.08,p<0.001),为无菌翻修者的1.87倍(95%CI 1.11-3.15,p=0.019);肠球菌感染者的死亡风险为其他细菌感染者的3.10倍(95%CI 1.66-5.81,p<0.001)。

要点

  • 初次全髋关节置换后1年内因PJI翻修的患者死亡率为8%(95%CI 6%-11%)。
  • 因PJI翻修者调整后相对死亡风险为未翻修者的2.18倍(95%CI 1.54-3.08,p<0.001)。
  • 肠球菌感染的全髋关节置换患者死亡风险为其他细菌感染者的3.10倍(95%CI 1.66-5.81,p<0.001)。

核心结论

  • 初次全髋关节置换后1年内因假体周围感染(PJI)翻修会增加翻修术后第一年的死亡风险。
  • 作者认为本研究应推动进一步研究PJI的预防以及患者风险,以期降低全髋关节置换患者总体及PJI患者的死亡率。

研究设计与样本

  • 基于丹麦髋关节置换登记库的全国性队列研究,纳入2005至2014年在丹麦实施的初次全髋关节置换。
  • 登记库数据与微生物数据库、患者国家登记库及民事登记系统链接,获取微生物学、合并症和生命状态数据。
  • 丹麦所有公立和私立医院均强制上报登记库,初次全髋关节置换登记完整性为98%,翻修为92%(2016年年报)。
  • 共识别59954例患者的68504例初次全髋关节置换,其中445例因PJI翻修、1350例因其他原因翻修、66709例未翻修。
  • 随访自初次全髋关节置换植入起至死亡或随访满1年,若发生翻修则至翻修日期后1年。

主要发现

  • 初次全髋关节置换后1年内,因PJI翻修的患者中有8%(95%CI 6%-11%)死亡。
  • 因PJI翻修者与未因任何原因翻修者相比,调整后相对死亡风险为2.18(95%CI 1.54-3.08,p<0.001)。
  • 因PJI翻修者与无菌翻修者相比,调整后相对死亡风险为1.87(95%CI 1.11-3.15,p=0.019)。
  • 肠球菌感染的全髋关节置换患者与其他细菌感染者相比,死亡风险为3.10(95%CI 1.66-5.81,p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Revision for prosthetic joint infection (PJI) has a major effect on patients' health but it remains unclear if early PJI after primary THA is associated with a high mortality. QUESTIONS/PURPOSES: (1) Do patients with a revision for PJI within 1 year of primary THA have increased mortality compared with patients who do not undergo revision for any reason within 1 year of primary THA? (2) Do patients who undergo a revision for PJI within 1 year of primary THA have an increased mortality risk compared with patients who undergo an aseptic revision? (3) Are there particular bacteria among patients with PJI that are associated with an increased risk of death? METHODS: This population-based cohort study was based on the longitudinally maintained Danish Hip Arthroplasty Register on primary THA performed in Denmark from 2005 to 2014. Data from the Danish Hip Arthroplasty Register were linked to microbiology databases, the National Register of Patients, and the Civil Registration System to obtain data on microbiology, comorbidity, and vital status on all patients. Because reporting to the register is compulsory for all public and private hospitals in Denmark, the completeness of registration is 98% for primary THA and 92% for revisions (2016 annual report). The mortality risk for the patients who underwent revision for PJI within 1 year from implantation of primary THA was compared with (1) the mortality risk for patients who did not undergo revision for any reason within 1 year of primary THA; and (2) the mortality risk for patients who underwent an aseptic revision. A total of 68,504 primary THAs in 59,954 patients were identified, of those 445 primary THAs underwent revision for PJI, 1350 primary THAs underwent revision for other causes and the remaining 66,709 primary THAs did not undergo revision. Patients were followed from implantation of primary THA until death or 1 year of followup, or, in case of a revision, 1 year from the date of revision. RESULTS: Within 1 year of primary THA, 8% (95% CI, 6%-11%) of patients who underwent revision for PJI died. The adjusted relative mortality risk for patients with revision for PJI was 2.18 (95% CI, 1.54-3.08) compared with the patients who did not undergo revision for any cause (p < 0.001). The adjusted relative mortality risk for patients with revisions for PJI compared with patients with aseptic revision was 1.87 (95% CI, 1.11-3.15; p = 0.019). Patients with enterococci-infected THA had a 3.10 (95% CI, 1.66-5.81) higher mortality risk than patients infected with other bacteria (p < 0.001). CONCLUSIONS: Revision for PJI within 1 year after primary THA induces an increased mortality risk during the first year after the revision surgery. This study should incentivize further studies on prevention of PJI and on risk to patients with the perspective to reduce mortality in patients who have had THA in general and for patients with PJI specifically. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Gundtoft PH, Pedersen AB, Varnum C, et al. Increased Mortality After Prosthetic Joint Infection in Primary THA. Clin Orthop Relat Res. 2017. PMID: 28236084. doi:10.1007/s11999-017-5289-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。